August 28, 2017
FDA OK’s Taipei-based company’s submissing for Naldebain in U.S.
Lumosa Herapeutics said Monday that the FDA has confirmed its submission of the NDA of LT1001 Naldebain in the US. Naldebain IM injection has received market authorization and launched in Taiwan as the world’s first 7-day long-acting analgesic injection for moderate to severe post-operative pain.